You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethaqualone
Accession NumberDB04833
TypeSmall Molecule
GroupsIllicit, Withdrawn
DescriptionMethaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. Its use peaked in the early 1970s as a hypnotic, for the treatment of insomnia, and as a sedative and muscle relaxant. It has also been used illegally as a recreational drug, commonly known as Quaaludes, Sopors, Ludes or Mandrax (particularly in the 1970s in North America) depending on the manufacturer. Since at least 2001, it has been widely used in South Africa, where it is commonly referred to as "smarties" or "geluk-tablette" (meaning happy tablets). Clandestinely produced methaqualone is still seized by government agencies and police forces around the world. [Wikipedia]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
QuaaludeRorer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7ZKH8MQW6T
CAS number72-44-6
WeightAverage: 250.2952
Monoisotopic: 250.11061308
Chemical FormulaC16H14N2O
InChI KeyInChIKey=JEYCTXHKTXCGPB-UHFFFAOYSA-N
InChI
InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3
IUPAC Name
2-methyl-3-(2-methylphenyl)-3,4-dihydroquinazolin-4-one
SMILES
CC1=CC=CC=C1N1C(C)=NC2=CC=CC=C2C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolines
Alternative Parents
Substituents
  • Quinazoline
  • Toluene
  • Pyrimidone
  • Benzenoid
  • Pyrimidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of insomnia, and as a sedative and muscle relaxant.
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include delirium, convulsions, muscle spasms or seizure, cardiac arrest, shortness or loss of breath, vomiting or nausea, and coma or death. The LD50 for mice is 1250 mg/kg and for rats is 326 mg/kg (Strasenburg Labs).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9953
Blood Brain Barrier+0.9921
Caco-2 permeable+0.8171
P-glycoprotein substrateNon-substrate0.7737
P-glycoprotein inhibitor IInhibitor0.6427
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.8537
CYP450 2C9 substrateNon-substrate0.6892
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6475
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.9593
CYP450 2C19 inhibitorNon-inhibitor0.8585
CYP450 3A4 inhibitorNon-inhibitor0.8509
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5384
Ames testAMES toxic0.5126
CarcinogenicityNon-carcinogens0.9142
BiodegradationNot ready biodegradable0.9488
Rat acute toxicity2.8349 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9864
hERG inhibition (predictor II)Non-inhibitor0.61
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0407 mg/mLALOGPS
logP2.54ALOGPS
logP3.17ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity77.11 m3·mol-1ChemAxon
Polarizability27.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Potential Analgesics. Part I. Synthesis of substituted 4-quinazolones, I. K. Kacker and S. H. Zaheer, J. Ind. Chem. Soc. 28 (1951), pp. 344–346.

General ReferencesNot Available
External Links
ATC CodesN05CM01N05CX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methaqualone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methaqualone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methaqualone.
adipiplonThe risk or severity of adverse effects can be increased when Methaqualone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methaqualone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methaqualone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methaqualone.
AmiodaroneThe metabolism of Methaqualone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methaqualone.
AmoxapineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amperozide.
AprepitantThe serum concentration of Methaqualone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.
ArticaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Asenapine.
AtazanavirThe metabolism of Methaqualone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Methaqualone can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Azaperone.
AzelastineMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methaqualone.
BaclofenThe risk or severity of adverse effects can be increased when Methaqualone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methaqualone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methaqualone is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Methaqualone can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Methaqualone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Methaqualone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Methaqualone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
BrimonidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methaqualone.
BrompheniramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methaqualone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methaqualone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methaqualone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methaqualone.
ButacaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methaqualone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methaqualone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methaqualone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methaqualone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methaqualone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methaqualone.
CarisoprodolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carisoprodol.
CeritinibThe serum concentration of Methaqualone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methaqualone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methaqualone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methaqualone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methaqualone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methaqualone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methaqualone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methaqualone.
CitalopramThe risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram.
ClarithromycinThe metabolism of Methaqualone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Methaqualone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methaqualone is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methaqualone.
ClotrimazoleThe metabolism of Methaqualone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methaqualone.
CobicistatThe metabolism of Methaqualone can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methaqualone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methaqualone.
ConivaptanThe serum concentration of Methaqualone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Methaqualone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.
CyclosporineThe metabolism of Methaqualone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Methaqualone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methaqualone.
DapoxetineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dapoxetine.
DarunavirThe metabolism of Methaqualone can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Methaqualone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Methaqualone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Methaqualone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Methaqualone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methaqualone.
DesipramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Detomidine.
DexamethasoneThe serum concentration of Methaqualone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methaqualone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methaqualone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methaqualone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methaqualone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methaqualone.
DifenoxinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methaqualone.
DihydroergotamineThe metabolism of Methaqualone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methaqualone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methaqualone.
DiltiazemThe metabolism of Methaqualone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methaqualone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methaqualone.
DoramectinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Doxepin.
DoxycyclineThe metabolism of Methaqualone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
DoxylamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methaqualone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
DronedaroneThe metabolism of Methaqualone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methaqualone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methaqualone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methaqualone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methaqualone.
EfavirenzThe serum concentration of Methaqualone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Methaqualone is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methaqualone.
EntacaponeThe risk or severity of adverse effects can be increased when Methaqualone is combined with Entacapone.
EnzalutamideThe serum concentration of Methaqualone can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Methaqualone can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Methaqualone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methaqualone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methaqualone.
EthanolMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methaqualone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone.
EthosuximideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methaqualone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methaqualone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methaqualone.
EtidocaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.
EtoperidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methaqualone.
EtravirineThe serum concentration of Methaqualone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methaqualone.
FenfluramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methaqualone.
FexofenadineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Flibanserin.
FluconazoleThe metabolism of Methaqualone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methaqualone.
FlunarizineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methaqualone.
FluoxetineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methaqualone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methaqualone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methaqualone.
FluspirileneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluvoxamine.
FluvoxamineThe metabolism of Methaqualone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Methaqualone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Methaqualone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fospropofol.
Fusidic AcidThe serum concentration of Methaqualone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methaqualone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methaqualone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methaqualone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methaqualone.
GuanfacineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methaqualone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methaqualone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methaqualone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methaqualone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methaqualone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methaqualone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
HydroxyzineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Hydroxyzine.
IdelalisibThe serum concentration of Methaqualone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Iloperidone.
ImatinibThe metabolism of Methaqualone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Indalpine.
IndinavirThe metabolism of Methaqualone can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Methaqualone can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methaqualone.
IsradipineThe metabolism of Methaqualone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Methaqualone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Methaqualone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methaqualone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methaqualone.
KetobemidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ketobemidone.
KetoconazoleThe metabolism of Methaqualone can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methaqualone.
LevocabastineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methaqualone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methaqualone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methaqualone.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methaqualone.
LofentanilThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lofentanil.
LopinavirThe metabolism of Methaqualone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methaqualone.
LovastatinThe metabolism of Methaqualone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methaqualone.
Lu AA21004The risk or severity of adverse effects can be increased when Methaqualone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Methaqualone can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methaqualone.
MelperoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methaqualone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methaqualone.
MetaxaloneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methaqualone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methaqualone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methaqualone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methaqualone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methaqualone.
MethsuximideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methaqualone.
MetyrosineMethaqualone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone.
MifepristoneThe metabolism of Methaqualone can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Methaqualone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
MirtazapineMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methaqualone.
MitotaneThe serum concentration of Methaqualone can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Methaqualone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methaqualone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methaqualone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.
NabiloneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nabilone.
NafcillinThe serum concentration of Methaqualone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methaqualone.
NefazodoneThe metabolism of Methaqualone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Methaqualone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Methaqualone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Methaqualone can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Methaqualone can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methaqualone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Olanzapine.
OlaparibThe metabolism of Methaqualone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methaqualone.
OpiumThe risk or severity of adverse effects can be increased when Methaqualone is combined with Opium.
OrphenadrineMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methaqualone.
OsanetantThe risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant.
OsimertinibThe serum concentration of Methaqualone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methaqualone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methaqualone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methaqualone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methaqualone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methaqualone.
PalbociclibThe serum concentration of Methaqualone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methaqualone.
ParaldehydeMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methaqualone.
ParoxetineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methaqualone.
PerampanelThe risk or severity of adverse effects can be increased when Methaqualone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Methaqualone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methaqualone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methaqualone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methaqualone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methaqualone.
PipamperoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pomalidomide.
PosaconazoleThe metabolism of Methaqualone can be decreased when combined with Posaconazole.
PramipexoleMethaqualone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methaqualone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methaqualone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methaqualone.
PrimidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methaqualone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methaqualone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methaqualone.
PromethazineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methaqualone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methaqualone.
PropoxycaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Methaqualone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methaqualone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methaqualone.
RamelteonThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ramelteon.
RanolazineThe metabolism of Methaqualone can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methaqualone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methaqualone.
RifabutinThe metabolism of Methaqualone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Methaqualone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Methaqualone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methaqualone.
RitonavirThe metabolism of Methaqualone can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Romifidine.
RopiniroleMethaqualone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methaqualone.
RotigotineMethaqualone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methaqualone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methaqualone.
SaquinavirThe metabolism of Methaqualone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methaqualone.
SertindoleThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methaqualone.
SildenafilThe metabolism of Methaqualone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Methaqualone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Methaqualone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sodium oxybate.
St. John's WortThe serum concentration of Methaqualone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.
SulfisoxazoleThe metabolism of Methaqualone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methaqualone.
SuvorexantThe risk or severity of adverse effects can be increased when Methaqualone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tasimelteon.
TelaprevirThe metabolism of Methaqualone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Methaqualone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methaqualone.
TetrabenazineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrodotoxin.
ThalidomideMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methaqualone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methaqualone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methaqualone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methaqualone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methaqualone.
TiagabineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tiagabine.
TiclopidineThe metabolism of Methaqualone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tizanidine.
TocilizumabThe serum concentration of Methaqualone can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Methaqualone is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methaqualone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methaqualone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.
TrazodoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methaqualone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methaqualone.
TrimipramineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methaqualone.
VenlafaxineThe metabolism of Methaqualone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Methaqualone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vilazodone.
VoriconazoleThe metabolism of Methaqualone can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methaqualone.
ZiconotideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zimelidine.
ZiprasidoneThe metabolism of Methaqualone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methaqualone.
ZonisamideThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methaqualone.
ZotepineThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methaqualone.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 15:07 / Updated on August 17, 2016 12:24